A groundbreaking take-at-home tablet, KCL-HO-1i, has emerged as a potential game-changer in cancer treatment, as per medical experts behind its development. This innovative drug aims to disrupt a defense mechanism utilized by tumors to shield themselves, thereby enhancing the efficacy of chemotherapy. Promising outcomes from early tests on mice have even shown the drug’s ability to sensitize chemotherapy-resistant tumors, hinting at a new approach to cancer therapy.
Chemotherapy, a widely used treatment for various cancers, functions by impeding the growth and division of cancer cells. However, its effectiveness can be compromised in some cases due to the body’s immune cells forming a protective barrier around tumors. This protective shield, facilitated by the production of heme oxygenase-1 (HO-1) protein by these cells, can diminish the impact of chemotherapy. KCL-HO-1i, developed at King’s College London, specifically targets this HO-1 protein to render tumors more receptive to treatment.
Professor James Arnold, leading the tumour immunology group at the university, highlighted the pivotal role of immune cells in impeding chemotherapy’s effectiveness. By leveraging KCL-HO-1i to target the enzyme produced by these cells, the researchers successfully enhanced the efficiency of beneficial immune cells and chemotherapy drugs. Notably, the drug’s impact extended to chemotherapy-resistant tumors in laboratory models, marking a significant advancement in cancer treatment strategies.
Designed for convenient at-home administration as a tablet in between chemotherapy sessions, KCL-HO-1i has exhibited promising results in mice, showcasing improved responsiveness of breast cancer tumors to various chemotherapy types. Researchers are optimistic about commencing trials involving breast cancer patients and individuals with other cancer types in the near future, potentially within two years. Professor James Spicer emphasized the importance of addressing the limitations of current chemotherapy treatments and expressed eagerness to evaluate KCL-HO-1i alongside established chemotherapy drugs in clinical settings.
Professor Miraz Rahman, specializing in medicinal chemistry at KCL, highlighted the potential of KCL-HO-1i as a complementary drug to existing cancer therapies, envisioning a scenario where more patients could benefit from available treatments while potentially reducing the necessity for aggressive cancer therapies. The establishment of Aethox Therapeutics, a spin-out company by the King’s College London scientists, underscores the translational potential of this innovative drug. Cancer Research UK, in collaboration with the Medical Research Council, has lent support to this study, recognizing the importance of optimizing current cancer treatments through innovative approaches like combination therapies.
Key Takeaways:
– KCL-HO-1i, a novel take-at-home tablet, shows promise in sensitizing chemotherapy-resistant tumors and enhancing cancer treatment.
– The drug targets the HO-1 protein produced by immune cells to improve the efficacy of chemotherapy and beneficial immune responses.
– Clinical trials involving breast cancer patients and other cancer types are anticipated to begin within two years, offering new hope for more effective cancer therapies.
– The development of Aethox Therapeutics and support from Cancer Research UK highlight the potential impact of this innovative drug on advancing cancer treatment strategies.
Read more on yahoo.com
You might also like: Microbial Magic: 101 Reasons to Love Being a Fermentation Scientist